Navigating Anthem (Elevance Health) Opdivo Prior Authorization

Opdivo (Nivolumab) in the Anthem Prior Authorization Landscape

Opdivo (nivolumab) is an immunotherapy medication primarily used in oncology, representing a high-volume prior authorization target across commercial, Medicare Advantage, and Medicaid managed care plans. As a specialty injectable/infusion, Opdivo typically falls under the medical benefit, though specific plan designs may vary. Understanding Anthem's specific medical policies and utilization management criteria, often referencing NCCN Compendium guidelines for oncology, is paramount for successful authorization.

Anthem's Prior Authorization Submission Channels for Opdivo

Anthem, operating under Elevance Health, directs prior authorization submissions through specific channels depending on the benefit and service type. For Opdivo, which is typically under the medical benefit, submissions are primarily handled through Availity Essentials, Anthem's multi-payer provider workspace. X12 278 transactions are also supported via clearinghouses, offering an automated pathway for eligible requests. Pharmacy benefit Opdivo, if applicable, routes through CarelonRx, often leveraging ePA partners like CoverMyMeds and Surescripts.

Key Submission Pathways

• **Medical Benefit (Primary):** Availity Essentials portal for initiation, benefit lookup, and document upload.
• **Electronic Data Interchange (EDI):** X12 278 transactions accepted via clearinghouses for medical PA.
• **Pharmacy Benefit (If Applicable):** CarelonRx's provider PA system or ePA via CoverMyMeds/Surescripts.
• **Specialty Drug Considerations:** Anthem's site-of-care and clinical-indication policies apply, with some categories potentially routing through Carelon for specific management.

Accessing Opdivo Medical Policies and Utilization Management Criteria

Anthem operating companies publish medical policies and clinical utilization management guidelines through provider sites accessible via Availity. Each state-licensed Anthem plan maintains its own medical-policy index, aligned with the broader Elevance Health corporate criteria framework. For oncology drugs like Opdivo, policies frequently cite criteria from the NCCN Compendium, alongside Anthem-developed or MCG-based criteria. It is crucial to reference the specific policy number, plan-state context, and effective date for accurate submission.

Turnaround Times and Electronic PA Posture

Prior authorization turnaround times for Anthem-licensed plans are governed by state insurance regulations for commercial lines. For Medicare Advantage, Medicaid managed care, and QHP-on-FFM lines, CMS-0057-F mandates a 72-hour standard and 24-hour expedited decision timeframe. Elevance Health has participated in Da Vinci Project initiatives, indicating a commitment to electronic prior authorization (ePA) standards like PAS, CRD, and DTR, though production conformance requires current public disclosure verification. Klivira integrates with these evolving standards to optimize ePA workflows.

Common Denial Reasons and Appeal Pathways for Opdivo

Anthem denials are typically returned via X12 277/835 transactions and Availity status updates. Common denial categories for specialty drugs like Opdivo include medical necessity/insufficient documentation, step therapy not completed (if applicable), site-of-service mismatch, or procedure not covered under the specific plan benefit. Appeals for standard medical PA route through the Anthem operating-company appeals process documented in the provider manual, with peer-to-peer reviews available to address clinical rationale.